![]() |
|
|
Vol. 304, Issue 1, 15-21, January 2003
Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia (H.L.K., M.J.K.), and Research Triangle Institute, Research Triangle Park, North Carolina (F.I.C.)
| |
Abstract |
|---|
|
|
|---|
Several studies have shown that repeated cocaine administration,
followed by withdrawal, alters dopamine transporter (DAT) levels in the
rat. These changes must arise from changes in either transporter
protein production or degradation, or both. Previously, our laboratory
developed an approach to measure the synthesis rate, degradation rate
constant, and half-life of DAT in the rat striatum and nucleus
accumbens after administration of the irreversible dopamine transporter
ligand, RTI-76
[3
-(3-p-chlorophenyl)tropan-2
-carboxylic acid
p-isothiocyanatophenylethyl ester hydrochloride].
Transporter binding was measured with [3H]GBR12935
[1-(2-[diphenylmethoxy]ethyl)-4-[3-phenylpropyl]piperazine]. These initial studies showed that: 1) the half-life of the transporter was between 2 and 3 days in these two brain regions; 2) pretreatment with dopamine D1 and D2 receptor agonists and antagonists over several
days differentially altered DAT half-lives in the striatum and nucleus
accumbens; and 3) pretreatment with cocaine for several days increased
the half-life of DAT by decreasing the degradation rate constant in
both brain regions. In the present study, we determined that repeated
pretreatment (10 days) with 20 mg/kg cocaine (i.p.) and a subsequent
withdrawal period (10 days) alters the dopamine transporter turnover in
the rat striatum, but not in the nucleus accumbens. Cocaine
pretreatment and withdrawal reduced the half-life of the transporter
protein from 2.1 days to 0.94 day in the striatum, but did not alter
the half-life of 2.2 days in the nucleus accumbens. The results
indicate the complex and long-lasting effects of cocaine administration
on cellular processes. The mechanism(s) of these effects remains to be elucidated.
| |
Introduction |
|---|
|
|
|---|
Although
cocaine binds to dopamine, serotonin, and norepinephrine transporters
with similar affinities, many of the stimulant and reinforcing effects
of cocaine in rodents and nonhuman primates have been attributed to its
action at the dopamine transporter (DAT) protein (Ritz et al., 1987
;
Bergman et al., 1989
; Kuhar et al., 1991
; Wise et al., 1996
; Wilcox et
al., 1999
). By binding to DAT, cocaine prevents the reuptake of
extrasynaptic dopamine, thus increasing levels of this neurotransmitter
in the synapse, and thereby influencing behavior (Di Chiara and
Imperato, 1988
; Kalivas and Duffy, 1990
). In rodents, repeated exposure
to cocaine can alter levels of DAT mRNA and protein, although the
nature of these changes has been inconsistent and seems to be
influenced by many factors, including route of administration, dose,
and withdrawal period (Kuhar and Pilotte, 1996
).
Chronic cocaine treatment produced decreases in DAT mRNA levels in the
ventral tegmental area (VTA) and substantia nigra in several studies
(Xia et al., 1992
; Burchett and Bannon, 1997
; Letchworth et al., 1997
).
In contrast, DAT protein binding was unaltered in the VTA and
substantia nigra, but increased in the anterior nucleus accumbens
following chronic cocaine treatment (Letchworth et al., 1997
). Some
studies have found a short-term increase followed by a decrease in DAT
binding in the nucleus accumbens after repeated cocaine treatment
(Pilotte et al., 1996
).
Withdrawal from repeated cocaine treatment has also been found to
induce changes in DAT mRNA and protein levels. Again, these reported
changes have been inconsistent. A 10- to 14-day withdrawal period after
repeated cocaine administration resulted in a decrease in binding to
DAT protein in the nucleus accumbens but not in the striatum (Cerruti
et al., 1994
; Boulay et al., 1996
) or in the substantia nigra (Xia et
al., 1992
). Yet another study found increased DAT binding in the
striatum, but not in the nucleus accumbens, after 3 days of withdrawal
from repeated cocaine (Claye et al., 1995
). After withdrawal from
chronic cocaine, DAT mRNA levels in the VTA were decreased in one study
(Cerruti et al., 1994
) but increased (Arroyo et al., 2000
) in another
study and unchanged in a third study (Maggos et al., 1997
). DAT mRNA
levels were unchanged in the substantia nigra (Xia et al., 1992
; Arroyo et al., 2000
) after withdrawal from chronic cocaine treatment.
The level of DAT protein at any given time is due to the balance
between the synthesis and degradation rates of the protein. Previously,
in our laboratory, we developed an approach to determine the turnover
kinetics of the DAT protein in the rat striatum and nucleus accumbens
using the irreversible DAT ligand, RTI-76
[3
-(3-p-chlorophenyl)tropan-2
-carboxylic acid
p-isothiocyanatophenylethyl ester hydrochloride]
(Fleckenstein et al., 1996
), and determined that the half-life of this
protein is 2 to 3 days in both brain regions (Kimmel et al., 2000
,
2001
). In a previous study, acute (3 days) treatment with cocaine
increased the half-life of DAT in both the striatum and the nucleus
accumbens (Kimmel et al., 2001
). In the present study, we determined
the DAT synthesis rate (r) and degradation rate constant
(k) in the rat striatum and nucleus accumbens following a
10-day withdrawal period from 10 days of cocaine administration. In
addition, to correlate the observed biochemical changes with behavioral
changes, we determined the locomotor-stimulating effects of cocaine in rats pretreated with saline or cocaine for 10 days followed by a 10-day
withdrawal period.
| |
Materials and Methods |
|---|
|
|
|---|
Animals. Male Sprague-Dawley rats (225-250 g; Charles River, Raleigh, NC) were grouped three per cage with food and water available at all times. Animals were housed in a colony room with a 12-h light/dark cycle. The animals were maintained in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals (NIH/85-23), and all experimental protocols were approved by the Institutional Animal Care and Use Committee of Emory University.
Cocaine Pretreatment, Withdrawal, and RTI-76 Administration.
Animals (n = 80) were treated once per day with a
single injection of 20 mg/kg cocaine i.p. or saline i.p. for 10 consecutive days. Following these 10 days of cocaine or saline
pretreatment, all animals were left untreated for another 10 days. On
the 11th day following the final cocaine or saline injection, animals
were anesthetized with 400 mg/kg chloral hydrate (i.p.) and placed in a
stereotaxic frame. All rats were given a single unilateral injection of
either 100 nmol of RTI-76 or saline in the right lateral ventricle.
Stereotaxic coordinates used relative to bregma were:
anteroposterior =
0.8, mediolateral =
1.4,
dorsoventral =
4.0. A 25-µl Hamilton syringe was used to
inject 10 µl of the RTI-76 solution over a 1-min period. Upon
completion of the injection, the needle was kept in place for 3 min to
minimize the back flow of the solution. Since RTI-76 is a light- and
temperature-sensitive compound, all manipulations were done under
low-light conditions, and the containers were wrapped in foil and kept
on ice. Animals were allowed to recover under a warming lamp until they
regained consciousness and then returned to their home cages.
Preparation of Membranes.
Rats (n = 3-4)
were rapidly decapitated at different time points after RTI-76
injection (1, 2, 3, 4, and 7 days). Brains were removed immediately and
placed in cold saline. The olfactory tubercles were removed with the
aid of fine forceps, exposing the diagonal bands of Broca. A razor
blade was used to cut away the frontal cortex and to dissect the
nucleus accumbens from both hemispheres. The pair of nucleus accumbens
was pooled for each animal, for a total weight of 10 to 20 mg. Fine
forceps were used to remove the right striatum, weighing 20 to 30 mg.
All tissues were removed rapidly and frozen on dry ice, and then stored
at
80°C until assayed.
[3H]GBR12935 Binding. After the final centrifugation, the tissue pellet was resuspended in buffer for a final concentration of 5 mg of wet tissue weight/ml. Polystyrene test tubes were filled with 1.5 ml of buffer (50 mM Tris-HCl, pH 7.7 at 24°C, containing 120 mM NaCl and 0.01% bovine serum albumin), 100 µl of 5 µM mazindol (final concentration) or buffer, 400 µl of radioligand, and 40 µl of tissue suspension for a total volume of 2.04 ml. Tubes were incubated at room temperature for 60 min, and the incubations were terminated by rapid filtration over Whatman GF/B filters that were pretreated with 0.05% polyethylenimine. The filters were rinsed three times with 4 ml of ice-cold buffer, and the radioactivity remaining on the filters was measured by conventional liquid spectrometry.
Drugs.
RTI-76 was prepared as previously reported (Carroll
et al., 1992
). Cocaine hydrochloride was obtained from the National
Institute of Drug Abuse, National Institutes of Health (Bethesda, MD).
[3H]GBR12935 was obtained from PerkinElmer Life
Sciences (Boston, MA). Bovine serum albumin, chloral hydrate,
mazindol hydrochloride, polyethylenimine, and potassium chloride were
obtained from Sigma-Aldrich (St. Louis, MO). Sodium chloride was
obtained from Fisher Scientific (Pittsburgh, PA). Tris hydrochloride
and Tris base were obtained from EM Science (Gibbstown, NJ). Cocaine
hydrochloride, chloral hydrate, and RTI-76 were dissolved in 0.9%
saline, and compounds used in the binding assay were dissolved in the
appropriate buffer.
Binding Data Curve Fitting. Bmax values were determined in each binding assay by fitting a nonlinear least-squares analysis and by a linear Scatchard plot, both giving similar results. Time course data were analyzed using GB-STAT v. 6.5 (Dynamic Microsystems Inc., Silver Spring, MD) to perform a two-way analysis of variance (systemic drug treatment versus time). Tukey's post hoc test was used to determine differences between groups.
Calculation of Receptor Kinetic Parameters.
The half-life of
recovery of [3H]GBR12935 binding to DAT in the
striatum and the nucleus accumbens following inactivation by RTI-76 was
determined, assuming a zero-order transporter production rate and a
first-order transporter degradation rate. The repopulation kinetics of
a transporter after irreversible inactivation can be defined by the
monoexponential equation: Bt = (r/k)(1
e
kt (eq. 1) (Mauger et al.,
1982
; Sladeczek and Bockaert, 1983
). Here,
Bt is the transporter concentration
(fmol/mg protein) at time t, r is the transporter
production rate (fmol/mg protein/h), and k is the
transporter degradation rate constant (h
1). As
time nears infinity, transporter recovery reaches steady-state levels
(Bss). The term
e
kt approaches 0, so that eq.
1 may be restated as: Bt = Bss = r/k (eq.
2). Bt and
Bss are derived from pooled data at
each time point.
e
kt) then
ln[Bss/(Bss
Bt)] = kt (eq. 3). This is an equation for a
straight line (y = mx + b, where
b = 0). From our experiments, where we have the
Bmax
(Bss) in control animals and in the
RTI-76-treated animals at each time point
(Bt), we can obtain k from the
slope of the plot
ln[Bss/(Bss
Bt)] versus time. The time to reach any particular percentage of Bss
values is dependent on k but not on r. Therefore,
any changes in k would change the time needed to reach a
certain percentage of Bss. To
determine the half-life of recovery, i.e., t = t1/2, let
Bt = Bss/2 and eq. 3 becomes ln 2 = kt1/2(t1/2 = ln 2/k = 0.693/k). Since we have the
experimentally determined Bss and the
k values, we can obtain r from restating eq. 2 as
r = kBss. In these
studies, Bss was taken to be the
concentration of recoverable transporters
(Bmax average of saline controls
residual Bmax at 1 day after RTI-76 treatment).
Locomotor Activity. Locomotor activity was measured using eight Digiscan animal activity monitors (AccuScan Instruments, Inc., Columbus, OH). Rats (250-274 g) received 0.9% saline (i.p.) (n = 8) or 20 mg/kg cocaine (i.p.) (n = 8) once daily for 10 consecutive days. Immediately after injection, animals were placed individually inside a polycarbonate cage (16.5 × 16 × 12 inches), contained inside of an activity monitor. Locomotor activity was monitored by infrared light beam sensors (eight beams per side) located on two opposing sides of the monitor. Activity was measured with a Digiscan analyzer and saved to a data file for subsequent analyses. Data were collected in 10-min intervals for 180 min. During the 10-day withdrawal period, animals did not receive any injections, but they were placed into the testing chambers and behavior was recorded for 180 min as described above. All rats were habituated to the locomotor activity chamber for at least 5 days before testing.
Data Analysis. The locomotor stimulant effects of saline, cocaine, or withdrawal were analyzed by a two-factor repeated measures analysis of variance, followed by a Tukey's post hoc test for multiple pairwise comparisons. Differences were considered statistically significant if p < 0.05.
| |
Results |
|---|
|
|
|---|
As described under Materials and Methods, four groups of animals were prepared. The two main groups were pretreated with either cocaine or saline (i.p.) for 10 days and subjected to a withdrawal period. Each main group was then subdivided into and treated with either RTI-76 or saline (i.c.v.). Three to four animals were taken from each group at 1, 2, 3, 4, or 7 days after i.c.v. treatment for measurement of DAT binding (Bmax).
One day after i.c.v. treatment with RTI-76, DAT binding was
reduced (Figs. 1 and
2) and binding gradually returned to control levels over the seven-day period. Treatment with i.c.v. saline had no
effect on DAT binding, as expected. Linear transformation of the
recovery data (Figs. 3 and
4) as described under Materials and
Methods indicated that the half-life of the DAT protein in saline-pretreated animals was 2.1 days in the striatum and 2.2 days in
the nucleus accumbens (Tables 1 and
2). These values are similar to our earlier
findings (Kimmel et al., 2000
, 2001
).
|
|
|
|
|
|
However, pretreatment with cocaine and a subsequent withdrawal reduced the DAT protein half-life in the striatum by more than 50% to 0.94 day. The DAT protein half-life in the nucleus accumbens was unchanged. The corresponding degradation rate constant (k) in the striatum, which determines the half-life, was increased. This is reflected in the more rapid recovery after RIT-76 in Fig. 1 and by the steeper slope calculated in Fig. 3. The synthesis rate (r) in the striatum was also increased in the cocaine-pretreated group. The net effect of increasing both k and r was that the Bmax at full recovery, i.e., 7 days after RTI-76 administration, was not changed in cocaine-pretreated animals compared with saline-pretreated animals (Figs. 1 and 2). Thus, pretreatment with cocaine and withdrawal changed the intracellular dynamics of the transporter protein without altering its overall levels to any significant extent. Because the animals that received saline both i.c.v. and systemically had similar Bmax values at all the time points after i.c.v. treatment (Figs. 1 and 2), the changes observed in Bmax after cocaine and RTI-76 must be due to the administration of the drugs rather than to the handling, the systemic or i.c.v. injections or the surgeries. Also, as previously reported, Kd values were unchanged in all of the treatment groups.
Because the above findings suggested a persistent change in DAT
proteins in striatal dopamine neurons during withdrawal, we tested
behavioral effects both during and after cocaine administration. A
separate group of animals were pretreated either with saline (n = 8) or with cocaine (n = 8) daily
for 10 days, and their locomotor activity was measured for 3 h
each day. There was a significant effect of drug treatment
[F(1,14) = 87.1, p < 0.0001] and of
treatment day [F(20,335) = 9.4, p < 0.001] and of the interaction [F(20,335) = 7.8, p < 0.001]. Cocaine-pretreated animals exhibited an
initial sensitization to the locomotor effects of cocaine between
treatment days 1 and 2 (Fig. 5), and this
response leveled off during treatment days 3 to 10. Saline-pretreated
animals did not show any sensitization to their testing environment
during the treatment period. Cocaine-pretreated animals showed
significantly higher activity than did the saline-treated animals
[F(1,29) = 293.7, p < 0.0001] during
the 10-day treatment period as expected.
|
During the 10-day withdrawal period, cocaine-pretreated animals exhibited slightly higher locomotor activity than did the saline-pretreated rats (Fig. 5) [F(1,29) = 4.74, p = 0.038]. However, post hoc tests did not reveal any significant differences between the two pretreatment groups on any specific withdrawal day. After the 10th day of withdrawal, both groups received a single challenge injection of 20 mg/kg cocaine (Fig. 5A). Cocaine-pretreated animals exhibited a higher response to this challenge dose of cocaine than did the saline-pretreated animals, but this response was also not statistically different from locomotor activity measured after cocaine injection during days 2 to 10. After this challenge dose of cocaine, the saline-pretreated animals showed an increase in locomotor activity comparable with that of the first day of treatment in the cocaine-pretreated animals.
| |
Discussion |
|---|
|
|
|---|
The most striking finding of this study is that repeated cocaine
pretreatment followed by withdrawal altered DAT protein synthesis and
degradation rates in the striatum, but not in the nucleus accumbens.
The nucleus accumbens, as part of the mesolimbic dopamine system, is
thought to be important in psychomotor stimulant-induced locomotor
activity (Kelly and Iversen, 1976
; Mogenson and Nielsen, 1984
; Clarke
et al., 1988
; Delfs et al., 1990
) and in the reinforcing effects of
cocaine (Nestler, 1994
). The striatum, part of the nigrostriatal
system, is thought to have a role in motor activity, such as stereotypy
(Alexander and Crutcher, 1990
; Cote and Crutcher, 1991
) but also in
rewarded "habit" learning (Everitt and Wolf, 2002
; Kelley and
Berridge, 2002
). That we observed a difference in response of DAT after
cocaine pretreatment and withdrawal in these two brain regions
emphasizes that, despite their similarities, these are two distinct
brain regions with distinct functions and connectivity.
Earlier studies in this laboratory also found differences in the
effects of systemic pretreatment with various dopamine receptor agonists and antagonists on the DAT half-life in the striatum and
nucleus accumbens of rats (Kimmel et al., 2001
) and the results of the
present study can be examined in light of those earlier findings. In
the rat striatum, systemic pretreatment with D2 dopamine receptor
agonists caused a decrease in the DAT half-life, while D1 dopamine
receptor agonists were without effect (Kimmel et al., 2001
). Here, we
observed a similar decrease in DAT half-life in the striatum,
suggesting that D2 dopamine receptors or their signaling pathways may
be active under these conditions of cocaine withdrawal. We previously
found that pretreatment with D1 and D2 dopamine receptor agonists both
increased DAT half-life in the nucleus accumbens. Thus, in the present
study, the observed lack of change in DAT turnover is not explained by
the activation of either D1 dopamine receptors alone or D2 dopamine
receptors alone. Our current results suggest that these receptors may
have a low level of activity under the withdrawal conditions studied.
The mechanism for the lack of change in DAT turnover in the nucleus
accumbens remains to be elucidated.
Several studies have shown changes in dopaminergic function following
intermittent cocaine treatment and withdrawal. In rats, withdrawal from
self-administered and experimenter-administered cocaine resulted in an
increased response to the locomotor depressant effects of dopamine
receptor antagonists, suggesting a possible withdrawal-induced deficit
in dopaminergic function in the basal ganglia (Baldo et al., 1999
).
Repeated intermittent treatment with cocaine for 14 days followed by a
7-day withdrawal period resulted in a functional subsensitivity of
release-modulating dopamine D2 autoreceptors in the caudate (Jones et
al., 1996
) and in the nucleus accumbens (Davidson et al., 2000
) of
rats. If the dopamine autoreceptors are not as sensitive to
extrasynaptic dopamine levels, then this could lead to increased
stimulation of postsynaptic dopamine receptors, resulting in the
observed decrease in DAT turnover in the striatum by the mechanism
described above. In the present study, we focused on a single schedule
of cocaine administration and withdrawal. Different withdrawal periods from cocaine may very well produce different changes in DAT kinetics, similar to the different changes observed in dopamine neurons after
different cocaine withdrawal periods (Kuhar and Pilotte, 1996
).
Somewhat surprisingly, changes were found in the striatum and not in
the accumbens, whereas changes in DAT protein levels have been observed
in the accumbens but not in the striatum following treatment with
cocaine (Pilotte et al., 1994
, 1996
; Wilson et al., 1994
; Letchworth et
al., 1997
). However, some of the previous studies used a different
strain of rats (Lewis versus Sprague-Dawley) and a different route of
cocaine administration (continuous i.v. versus intermittent i.p.) from
that in the present study (Pilotte et al., 1994
, 1996
). Our present
data showed sustained changes in locomotor activity during withdrawal
from repeated cocaine pretreatment (Fig. 5), supporting changes in
striatal DAT, a brain region involved in locomotor effects in rodents
and other mammals.
The changes observed in the striatum following cocaine treatment and withdrawal were an increase in both r and k. The mechanism(s) underlying these changes in r and k are unknown at present. However, alterations in r and k presumably reflect changes in cellular processes such as protein synthesis, mRNA stabilization, DAT insertion into and retrieval from the cell membrane, and others.
These data also confirm those previously reported, suggesting that the
half-life of DAT in the striatum and nucleus accumbens is about 2 days
(Kimmel et al., 2000
, 2001
). An additional important finding is that
repeated handling of the animals and systemic injections of saline
prior to i.c.v. administration of RTI-76 did not alter DAT protein
kinetics. The present data suggest that this treatment design does not
produce any long-term side effects in and of itself; the observed
changes in the cocaine-pretreated animals are most likely due to the
repeated exposure to the drug and subsequent withdrawal, not due to the
physical manipulations involved.
One question that remains to be addressed is that of the effect of repeated, daily administration of cocaine without withdrawal upon DAT protein kinetics. A review of the literature reveals discrepancies in the effects of repeated cocaine treatment upon DAT levels (see the introduction). In addition, it is important to elucidate what aspect of cocaine binding to DAT causes these subsequent changes in DAT protein kinetics. Although cocaine binds directly to DAT, many of its effects are due to increases in synaptic dopamine, which then binds to pre- and postsynaptic dopamine receptors.
In summary, repeated daily pretreatment with cocaine followed by
withdrawal results in a trend toward sensitization to the locomotor
effects of a subsequent cocaine challenge and a change in DAT protein
turnover in the striatum of the rat. Although the nucleus accumbens has
been associated with sensitization to the locomotor effects of cocaine
in rats (Pierce and Kalivas, 1995
; Filip and Siwanowicz, 2001
;
Todtenkopf et al., 2002
), DAT kinetics in this brain region were not
altered by cocaine pretreatment and withdrawal in this study. However,
the present results indicate that the effects of cocaine are
long-lasting and that these biochemical changes may be partly
responsible for the withdrawal symptoms observed in cocaine addicts.
| |
Acknowledgments |
|---|
We thank Stephen C. Payne and Andrew R. Joyce for expert technical assistance.
| |
Footnotes |
|---|
Accepted for publication September 11, 2002.
Received for publication April 24, 2002.
This research was supported by Grants RR00165 (M.J.K.), DA00418 (M.J.K.), DA005935 (H.L.K.), and DA05477 (F.I.C.), all from the National Institutes of Health.
DOI: 10.1124/jpet.102.038018
Address correspondence to: Heather L. Kimmel, Division of Neuroscience, Yerkes National Primate Research Center, Emory University, 954 Gatewood Rd. NE, Atlanta, GA 30341. E-mail: hlkimme{at}emory.edu
| |
Abbreviations |
|---|
DAT, dopamine transporter;
VTA, ventral
tegmental area;
RTI-76, 3
-(3-p-chlorophenyl)tropan-2
-carboxylic acid
p-isothiocyanatophenylethyl ester hydrochloride;
GBR12935, 1-(2-[diphenylmethoxy]ethyl)-4-[3-phenylpropyl]piperazine.
| |
References |
|---|
|
|
|---|
-(3p-chlorophenyl)tropan-2
-carboxylic acid p-isothiocyanatophenylethyl ester hydrochloride].
J Pharmacol Exp Ther
279:
200-206
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||